und keiner hier dabei

Thema bewerten
Beiträge: 10
Zugriffe: 6.157 / Heute: 4
Athersys -   $ +0,00% Perf. seit Threadbeginn:   -100,00%
 
dEsiSchES:

und keiner hier dabei

2
22.12.09 17:25
>4x bewertet

Werbung

Entdecke die beliebtesten ETFs von SPDR

SPDR MSCI Europe Financials UCITS ETF
Perf. 12M: +27,55%
SPDR MSCI Europe Communication Services UCITS ETF
Perf. 12M: +23,67%
SPDR MSCI Europe Utilities UCITS ETF
Perf. 12M: +22,84%
SPDR S&P U.S. Utilities Select Sector UCITS ETF
Perf. 12M: +22,55%
SPDR MSCI World Utilities UCITS ETF
Perf. 12M: +20,07%

dEsiSchES:

Athersys shares continue rally on Pfizer deal

2
22.12.09 17:38
(Reuters) - Shares of biotechnology company Athersys Inc (ATHX.O) continued their rally for the second day on Tuesday, a day after the company inked a deal with pharma giant Pfizer Inc (PFE.N) on its experimental stem cell therapy.

HOT STOCKS

Under the agreement, Pfizer will pay Athersys $6 million upfront and up to $105 million in milestones for Athersy's stem cell therapy, MultiStem, which is being developed for the treatment of inflammatory bowel disease.

Analyst Stephen Brozak of WBB Securities said, "this deal is an indication that Athersys is not only demonstrating confidence in the program, but also maintaining control of its destiny with regard to other, more advanced MultiStem applications, such as MultiStem for Bone Marrow Transplants and MultiStem for Acute Myocardial Infarctions (heart attack)."

Both the applications are being tested in an early stage clinical trial.

Brozak upgraded the stock to "buy" but reiterated his $8 price target on the shares.

Shares of the company were up 35 pct at $3.23 on Nasdaq. They rose to as much as $3.59 earlier in the session.

About 8 million shares changed hands in morning trade, more than 8 times their 10-day moving average volume.

(Reporting by Krishnakali Sengupta in Bangalore; Editing by Unnikrishnan Nair)

www.reuters.com/article/...L2P220091222?type=globalMarketsNews
Bewerten
>2x bewertet
dEsiSchES:

thx for black

 
22.12.09 17:39
Bewerten
>2x bewertet
dEsiSchES:

he polo10 nice work blackiblack

 
22.12.09 17:50
Bewerten
>1x bewertet
dEsiSchES:

mmh 4$ und zwei schwarze wow

 
22.12.09 18:11
Bewerten
>1x bewertet
jocyx:

stem cell therapy - wird interessant ...

4
22.12.09 19:00
Bewerten
>4x bewertet
jocyx:

@dEsiSchES, nicht über die Schwatten wundern,

 
22.12.09 20:04
die kommen von dem Obermelder hier bei ariva . Also ganz normaler Vorgang.
Bewerten
>2x bewertet
dEsiSchES:

oh aha ok typisch deutsch gelle

 
22.12.09 20:22
zum glueck bin ich in amerika (boston)
Bewerten
>5x bewertet
Anzeige: Ist das der Durchbruch für den KI-Biotech-Geheimtipp?

Potenzial riesig, Aktie günstig!
jocyx:

womit ist denn dieser Absturz begründet ?

 
29.12.09 22:48
Habe noch nichts gefunden ...

Nasdaq  4,19 $  -20,49%
Bewerten
Tifflor:

News

 
10.02.10 14:32
Feb. 10, 2010 (GlobeNewswire) --
CLEVELAND, Feb. 10, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has been granted U.S. patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions. Athersys also announced that it has been granted – and the opposition period has cleared – EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation, expansion, and usage.

The issued patents cover Athersys' proprietary scalable MultiStem® technology, which is an investigational stem cell therapy that has demonstrated therapeutic potential to treat a broad range of diseases and indications, including acute myocardial infarction, inflammatory bowel disease (IBD), bone marrow transplant support and ischemic stroke. Athersys announced in December 2009 a strategic partnership with Pfizer under which the companies will jointly develop MultiStem for IBD.

"These patents further expand our stem cell IP estate and offer additional validation of the strength and breadth of the Athersys IP portfolio," said William (B.J.) Lehmann, President and COO of Athersys. "We believe that these patents are especially important as they extend the coverage of the composition, isolation, differentiation and scalable manufacturing of non-embryonic stem cells that are core to our technology and product portfolio."

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Es gibt keine neuen Beiträge.
 Ich: 


Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Athersys Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  14 Athersys und Pfizer .... Chalifmann3 Vassago 11.10.23 12:05
3 13 Die Karten sind neu gemischt AnonymusNo1 Nobsy11 17.06.22 17:57
  10 --- Faktor X buran 18.03.14 06:47
2 9 und keiner hier dabei dEsiSchES Tifflor 10.02.10 14:32